March 23, 2023–(BUSINESS WIRE)–Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a prospective, randomized, controlled study. This study, “RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor” (clinicaltrials.gov NCT05540626), demonstrated that adding TAPS therapy to the patient’s care plan improved outcomes.
Cala TAPS Therapy for Essential Tremor Patients Improves Outcomes in a New Randomized Controlled Trial
Posted on March 29, 2023
Categories: ET News, ET Treatment, In the News